FibroBiologics’ (FBLG) Buy Rating Reaffirmed at D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $16.00 price objective on the stock.

A number of other brokerages also recently issued reports on FBLG. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of FibroBiologics in a report on Tuesday. Rodman & Renshaw began coverage on FibroBiologics in a research note on Thursday, December 12th. They issued a “buy” rating and a $12.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, FibroBiologics has a consensus rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Trading Down 5.3 %

Shares of FBLG stock opened at $0.90 on Tuesday. FibroBiologics has a twelve month low of $0.90 and a twelve month high of $13.59. The stock has a 50 day moving average of $1.30 and a 200 day moving average of $2.16.

Hedge Funds Weigh In On FibroBiologics

A number of institutional investors have recently modified their holdings of the company. Intech Investment Management LLC acquired a new stake in FibroBiologics during the fourth quarter worth approximately $25,000. Virtu Financial LLC acquired a new stake in shares of FibroBiologics during the fourth quarter worth $30,000. The Manufacturers Life Insurance Company acquired a new stake in shares of FibroBiologics during the third quarter worth $32,000. Jane Street Group LLC purchased a new stake in shares of FibroBiologics in the third quarter valued at $37,000. Finally, Raymond James Financial Inc. acquired a new position in FibroBiologics in the fourth quarter valued at $37,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.